WHWK

Business Context and Reporting Period

Company: Zeta Acquisition Corp. II (Note: Input metadata referenced "Whitehawk Therapeutics," but the filing text identifies the registrant as Zeta Acquisition Corp. II).

Reporting Period: Fiscal year ended December 31, 2008.

Business Model: The Company is a "blank check" shell company incorporated in Delaware on November 16, 2007. It has no specific business plan other than to seek a business combination (merger or acquisition) with an operating company. As of the filing date, the Company had not identified a target, conducted negotiations, or entered into any definitive agreements. It is classified as a development stage company and a smaller reporting company.

Key Financial Metrics

Capital Structure: 5,000,000 shares of Common Stock issued and outstanding as of March 31, 2009. No Preferred Stock issued. No debt outstanding as of December 31, 2008 (a $10,000 note payable to a stockholder was repaid in 2007).

Material Changes Versus Prior Period

• Cash Position: Cash and cash equivalents decreased significantly from $39,273 at December 31, 2007, to $7,508 at December 31, 2008, a reduction of $31,765.
• Liabilities: Current liabilities (accounts payable and accrued expenses) increased from $4,250 in 2007 to $6,108 in 2008.
• Equity: Total stockholders' equity declined from $35,023 in 2007 to $1,400 in 2008 due to the accumulation of operating losses.
• Operations: The Company continued to incur costs related to legal, accounting, and audit fees for SEC reporting requirements, with no revenue generation in either period.

Outlook, Risks, and Management Commentary

Liquidity and Capital Resources: The Company has nominal assets and no revenue. It is dependent on capital investment or financing from related parties to fund ongoing operations and search for a target. Management estimates it can meet costs for the next 12 months through existing treasury funds, fee deferrals, or additional loans from stockholders/management.

Going Concern: The financial statements are presented on a going concern basis, which raises substantial doubt about the Company's ability to continue as a going concern without additional financing.

Risks:

• Competition: Faces vast competition from other shell companies and well-financed entities for a limited number of business opportunities.
• Target Uncertainty: No assurance that a suitable target will be identified or that a transaction will be consummated.
• Dilution: Future acquisitions may result in substantial dilution to existing shareholders if the transaction is structured as a tax-free reorganization.
• Management Time: Officers and directors are engaged in outside business activities and devote limited time to the Company until an acquisition is identified.

Unusual Items: The Company utilizes office space and equipment of its management at no cost. There are no off-balance sheet arrangements.

Investor Verification Checklist

• Company Identity: Verify that the filing pertains to "Zeta Acquisition Corp. II" and not "Whitehawk Therapeutics, Inc." as suggested in the metadata.
• Cash Runway: Confirm the current cash balance ($7,508 as of 2008) and assess the likelihood of obtaining additional funding from related parties to sustain operations.
• Related Party Transactions: Review the extent of reliance on officers (John Pappajohn and Matthew P. Kinley) for funding and office space.
• Shareholder Dilution: Understand that in a potential merger, existing shareholders may retain less than 20% of the surviving entity.
• Management Track Record: Investigate the history of the management team with previous blank check companies (e.g., Healthcare Acquisition Corp., Zeta Acquisition Corp. I and III).